An extract of the fern Polypodium leucotomos (Difur®) modulates Th1/Th2 cytokines balance in vitro and appears to exhibit anti-angiogenic activities in vivo: Pathogenic relationships and therapeutic implications

Anticancer Research

Volumn 20, Issue 3 A, 2000, Pages 1567-1575

  Gonzalez, S ^a   Alcaraz, M V ^a   Cuevas, J ^f   Perez, M ^b   Jaen, P ^f   Alvarez Mon, M ^c   Villarrubia, Vicente G ^d,e  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^d Dpt de Immunología   (Spain)

^e Dpt de Inmunologia   (Spain)

^f NONE

Author keywords

Anti angiogenesis; Polypodium leukotomos; Th1 and Th2 cytokines; UVB irradiation

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIOXIDANT; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 6; POLYPODIUM LEUCOTOMOS EXTRACT; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; TH2 CELL;

ANGIOGENESIS INHIBITORS; ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; LEUKOCYTES, MONONUCLEAR; MICE; MICE, INBRED HRS; PLANT EXTRACTS; PLANTS, MEDICINAL; RADIODERMATITIS; TH1 CELLS; TH2 CELLS; ULTRAVIOLET RAYS;

EID: 0033863822     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (75)

1. Romagnani S: Induction of Th1 and Th2 responses: a key role for the natural immune response? Immunol Today 13: 379-81, 1992.
2. Trinchieri G: Inlerleukin-12: A proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adative immunity. Annu Rev Immunol 13: 251-76, 1995.
3. Garside P, McI Mowat A: Polarization of Th-cell responses: a phylogenetic consequence of nonspecific immune defence? Immunol Today 16: 220-3, 1995.
4. Villarruhia VG, Sanchez L, Alvárcz-Mon M: Las nuevas vacunas y la respuesta inmunologica. La mcmoria inmunologica.I. Respuesta humoral trente a respuesta celular. Med Clin (Barc) 107: 146-54, 1996.
5. Villarruhia VG, G Calvo C, Sada G: Las nuevas vacunas y la respuesta inmunológica. II. El entorno de la presentacion antigenica. Adyuvantes como inductores de linfocitos T-inductores de respuestas de mediacion celular. Med Clin (Barc) 107: 185-96, 1996.
6. Fearon DT, Locksley RM: The instructive role of innate immunity in the acquired immune response. Science 272: 50-4, 1996.
7. Villarrubia VG, Alvarez-Mon M, Chirigos MA, Herrerias JM: Virus de la hepatitis B (VHB) y la respuesta inflamatoria/inmunológica. I. El entomo natural de la presentacion antigénica y el caos inmunologico inducido por el virus. Rev Esp Enf Digest 89: 919-28, 1997.
8. Villarrubia VG, Herrerias JM, Alvarez-Mon M, Chirigos MA: Virus de la hepatitis B y la respuesta inflamatoria/inmunologica. II. Una nueva oportunidad de tratamiento de la infeccion cronica y una sugerencia para el tratamiento de otras enfermedades viricas persistentes. Rev Esp Enf Digest 90: 514-22, 1998.
9. Mosmann TR, Coffman RL: TH1 and TH2 cells: Different patterns of lynqphokine secretion lead to different functional properties. Annu Rev Immunol 7: 145-73, 1989.
10. Villarrubia VG, González P, Rodriguez Navarro S, García Calvo C, de las Heras M, Alvarez-Mon M: Patogenia inmunológica/inflamatoria del asma: El predominio Th2 y su relación con los mecanismos de desvío inmunológico durante las épocas fetal y neonatal. Implicaciones terapeuticas. Allergol et Immunopathol 27: 213-231, 1999.
11. Trinchieri G: Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv Immunol 70: 83-243, 1998.
12. Gately MK, Renzelti LM, Magram J, Stern AS, Adorini L, Gubler U, Presky DH: The interleukin-12/interleukin-12-receptor system: Role in normal and pathologic immune responses. Annu Rev Immunol 16: 495-521, 1998.
13. Reich K, Bruck M, Grafe A, Vente C, Neumann C, Garbe C: Treatment of psoriasis with interleukin-10. J Invest Dermatol 111: 1235-6, 1998.
14. Taylor JL, Grossberg SE: The effects of interferon-a on the production and action of othercytokines.SeminOncol 25(SI): 23-9, 1998.
15. Butler LD, Mohler KM, Layman NK, Cain RL, Riedl PE, Puckett LD, Bendele AM: Interleukin-2 induced systemic toxicity: Induction of mediators and immunopharmacologic intervention. Immunopharmac Immunotox 11: 445-87, 1989.
16. Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Karsen G, Atkins MB, et al: Effects of a single-dose interleukin-12 exposure on interleukin-12 associated toxicity and interferon-γ production. Blood 90: 2541-8, 1997.
17. Bogdan C, Vodovotz Y, Nathan C: Macrophage-deactivation by interleukin 10. J Exp Med 174: 1549-55, 1991.
18. 8+ T cells resulting in a failure to lyse tumor cells. Bloody 93: 1634-42, 1999.
19. + progenitors by tumor cells: role of inlerleukin-6 and macrophage colony-stimulating factor. Blood 92: 4778-91, 1998.
20. Motro B, Itin A, Sachs L, Keshet E: Patterns of interleukin 6 gene expression in vivo suggests a role for this cytokine in angiogenesis. Proc Natl Acad Sci USA 87: 3092-6, 1990.
21. Hipolito Ruiz: Disertaciones. Sobre la raiz de la ratanhia de la calaguala y de la china y acerca de la yerba llamada canchalagua. En: Biblioteca de Clasicos de la Farmacia Espanola. Coeditado por la Fundacion de Ciencias de la Salud, la Sociedad Estatal Quinto Centenario y el Real Jardin Botanico de Madrid. 1992.
22. Vargas J, Muhoz C, Osorio C, Garcia-Olivares E: Anapsos, an antipsoriatic drug which increases the proportion of suppressor cells in human peripheral blood. Ann Immunol (Institut Pasteur) 134C: 393-400, 1983.
23. Tuominen M, Bohlin L, Rolfsen W: Ethnopharmacological and clinical data as basis of pharmacognostic studies of the fem calaguala (Polypodium decumanum). In: 2nd Int Congress Ethnopharmacology. July 2-4. Uppsala, Sweden 1992.
24. Tuominen M, Bohlin I, Rolfsen W: Effects of Calaguala and an active principle, adenosine, on platelet activating factor. Planta Med 58: 306-10, 1992.
25. Brain S, Camp R, Dowd P, Black AK, Greaves M: The release of leukotriene B4-like material in biologically active amounts from the lesional skin of patients with psoriasis. J Invest Dermatol 83: 70-3, 1984.
26. Mallet AI, Cunningham FM: Structural identification of platelet-activating factor in psoriatic scale. Biochem Biophys Res Commun 126: 192-8, 1985.
27. Gonzalez S, Pathak MA: Inhibition of ultraviolet-induced formation of reactive oxygen species, lipid peroxidation, erythema and skin photosensitization by Polypodium leucotomos. Photodermatol Photoimmunol Photomed 12: 45-56, 1996.
28. Gonzalez S, Pathak MA, Cuevas J, Villarrubia VG, Fitzpatrick TB: Topical or oral treatment with an extract of Polypodium leucotomos prevents acute sunburn and psoralen-induced phototoxic reactions as well as depletion of Langerhans cells in human skin. Photomed Photoimmunol Photodermatol 13: 50-60, 1996.
29. de las Heras ME, Ledo E, Gonzalez S, Rocamora A, Ledo A: El extracto de Polypodium leucotomos (Difur), como adyuvante a Puvaterapia en el tratamiento de la psoriasis vulgar. Med Cután Iber Lat Am XXV/97: 103-7, 1999.
30. Rayward J, Villarrubia VG, Guillen C, Prieto A, Rodríguez-Zapata M, Sada G, Alvarez-Mon M: An extract of the fern Polypodium leucotomos inhibits human peripheral blood mononuclear cells proliferation in vitro. Int J Immunopharmac 19: 9-14, 1997.
31. Perez de las Casas O, Rodriguez E, Gonzalez P, Diaz-Flores L, Gonzalez F, Alarcó A: Aloinjertos cutaneos tras la administracion de Polipodium leucotomos (Estudio experimental). Rev Barc Quirurg 30: 303-11, 1987.
32. Tuominen M, Bohlin I, Lindbom L-O, Rolfsen W: Enhancing effect of extract of Polypodium leucotomos on the prevention of rejection on skin transplants in mice. Phytother Res 5: 234-36, 1991.
33. Alcaráz MV, Pathak MA, Rius F, Kollias N, Gonzalez S: An extract of Polypodium leucotomos appears to minimize certain photoaging changes in a hairless albino mouse animal model. Photodermatol Photoimmunol Photomed 15: 120-6, 1999.
34. Villarrubia VG, Gonzalez P, Rodriguez S, Brieva A, Garcia F, Guerrero A, et al: Inmunidad, inflamacion y oxidacion. Difur, extracto de Polypodium leucotomos (EPL): un inmunomodulador oral con propiedades fotoprotectoras. El concepto de fotoinmunoproteccion. (Sometido a publicacion).
35. Sempere JM, Rodrigo C, Campos A, Villalba JF, Diaz J: Effect of Anapsos (Polypodium leucotomos extract) on in vitro production of cytokines. Br J Clin Pharmacol 43: 85-9, 1997.
36. Murray HW: Interferon-gamma, the activated macrophage, and host defense against microbial challenge. Ann Intern Med 108: 595-608, 1988.
37. Berg DJ, Leach MW, Khun R, Rajewsky K, Muller W, Davidson NJ, Rennick D: Interleukin 10 but not interleukin 4 is a natural suppressant of cutaneous inflammatory responses. J Exp Med 182: 99-108, 1995.
38. Powrie F, Coffman RL: Inhibition of cell-mediated immunity by IL-4 and IL-10. Res Immunol 144: 639-437, 1993.
39. Taga K, Tosato G: IL-10 inhibits human T cell proliferation and IL-2 production. J Immunol 148: 1143-8, 1992.
40. Powrie F, Bean A, Moore KW: Interleukin-10. In: Cytokines in health and disease, 2nd edit (Remick DG, Friedland JS, ed) New York Marcel Dekker, Inc pp 143-52, 1997.
41. Rivas JM, Ullrich SE: Systemic suppression of delayed-type hypersensitivity by supernatants from W-irradiated keratinocytes. An essential role for keratinocyte-derived-IL-10. J Immunol 149: 3865-71, 1992.
42. Ferguson TA, Dube P, Griffith TS: Regulation of contact hypersensitivity by interleukin 10. J Exp Med 179: 1597-1604, 1994.
43. Kuhn R, Lohler J, Rennick D, Rajewski K, Muller W: Interleukin-10 deficient mice develop chronic enterocholitis. Cell 75: 263-74, 1993.
44. Powrie F, Leach MW, Mauze S, Menon S, Caddle LB, Coffman RL: Inhibition of Th1 responses prevents inflammatory bowel disease in seid mice reconstituted with CD45RBhi CD4+ T cells. Immunity 1: 553-62, 1994.
45. Romero Garrido JA: Efectos farmacologicos del extracto de Polypodium leucotomos en un modelo experimental de inflamacion intestinal. Tesis Doctoral. Dpt° de Farmacologia, Universidad de Granada (Espana) 1998.
46. Chernoff AE, Granowitz EV, Shapiro L, Vannier E, Lennemann G, Angel JB, Kennedy JS, et al: A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. J Immunol 154: 5492-9, 1995.
47. Schreiber S, Heinig T, Thiele HG, Raedler A: Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology 108: 1434-44, 1995.
48. Asadullah K, Sterry W, Stephanek K, Jasulatis D, Leupold M, Audring H, Volk HD, Döcke WD: IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. J Clin Invest 101: 783-94, 1998.
49. Corrales-Padilla H, Laínez HN, Pacheco JA: A new agent (hydrophilic fraction of Polypodium leucotomos) for management of psoriasis. Int J Dermatol 13: 276-82, 1974.
50. Kripke ML: Ultraviolet radiation and immunology: something new under the sun-Presidential address. Cancer Res 54: 6102-5, 1994.
51. Villarrubia VG, Gonzalez S, Cuevas J: Alteraciones inmunologicas provocadas por la radiacion ultravioleta. Su relacion patogenica con el fotoenvejecimiento y la aparicion de cancer de piel. Piel 11: 462-70, 1996.
52. Kimber I, Dearman RJ, Cumberbatch M, Huby RJD: Langerhans cells and chemical allergy. Curr Op Immunol 10: 614-9, 1998.
53. Cumberbatch M, Griffiths CEM, Tucker SC, Dearman RJ, Kimber I: Tumour necrosis factor-α induces Langerhans cell migration in humans. Br J Dermatol 41: 192-200, 1999.
54. Kock A, Schwarz T, Kirnbauer R, Urbanski A, Perry P, Ansel JC, Luger TA: Human keratinocytes are a source for tumor necrosis factor alpha: evidence for synthesis and release upon stimulation with endotoxin or ultraviolet light. J Exp Med 172: 1609-147, 1990.
55. Kirnbauer R, Kock A, Neuner P, Froster E, Krutman J, Urbanski A, el al: Regulation of epidermal cell interleukin-6 production by W light and corticosteroids. J Invest Dermatol 96: 484-9, 1991.
56. Gallo RL, Staszewski R, Granstein RD: Physiology and pathology of skin photoimmunology. In: Skin Immune System (SIS) (Bos JD, ed), Boca Raton FL, CRC Press, Inc. pp 381-401, 1990.
57. Kaaresn LL, Poulsen TD, de Fine Olivarius F, Wulf HC: Mast cells and elastosis in ultraviolet-irradiated hairless mice. Photodermatol Photoimmunol Photomed 11: 1-5, 1995.
58. Metcalfe DD, Costa JJ, Burd PR: Mast cells and basophils. In: Inflammation: Basic principles and clinical correlates (Gallin, JI, Goldstein IM, Snydermann R eds). New York, Raven Press Ltd. 1992, pp. 709-25.
59. Kessler DA, Langer RS, Pless NA, Folkman J: Mast cells and tumor angiogenesis. Int J Cancer 18: 703-3, 1976.
60. Dethlefsen SM, Matsuura N, Zetter BR: Tumor growth and angiogenesis in wild type and mast cell deficient mice. FASEB J4(3): A623 (Abstr 2070), 1990.
61. Liebovich SJ, Polverini PJ, Shepard HM, Wiseman DM, Shively V, Nusseir N: Macrophage-induced angiogenesis is mediated by tumour necrosis factor-a. Nature 329: 630-2, 1987.
62. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med 1: 27 31, 1995.
63. Folkman J: Antiangiogenic therapy. In: Cancer: Principles & Practice of Oncology, fifth edit, (DeVita Jr VT, Hellman S, Rosenberg SA, eds) Philadelphia, Lippincott-Raven Publishers, 1997; pp. 3075-85.
64. Villarrubia VG, Miles H, Araujo CE, Gonzalez P, Costa LA, Alvarez-Mon M: El comportamicnto paradojico del sistema inmunologico frente al cancer: Resistencia frente a promocion tumoral. De la nueva inmunopatogenia a los modernos tratamientos. (Sometido a publicacion).
65. Broide DH, Wasserman SI, Alvaro-Gracia J, Zvaifler NJ, Firestein GS: Transforming growth factor-β1 selectively inhibits IL-3-dependent mast cell proliferation without affecting mast cell function or differentiation. J lmmunol 143: 1591-7, 1989.
66. Grotendorst GR, Smale G, Pencev D: Production of transforming growth factor beta by human peripheral blood monocytes and neutrophils. J Cell Physiol 140: 396-402, 1989.
67. Roberts AB, Sporn MB: Transforming growth factor-beta: potential common mechanisms mediating its effects on embryogenesis, inflammation-repair, and carcinogenesis. Int J Radiat Appl Instrum (B) 14: 435-9, 1987.
68. Tabora JE: Efectos de la fracciön CF-4 de la calaguala (Polypodium leucotomos) sobre la estructura y el metabolismo del colageno en la rata albina. Tesis Doctoral. Facultad de Ciencias Medicas. Universidad Nacional Autonoma, Honduras, 1970.
69. Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, et al: Transforming growth factor type-beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 83: 4167-71, 1986.
70. Yang EY, Moses HL: Transforming growth factor B 1 -induced changes in cell migration, proliferation, and angiogenesis in the chicken chorioallantoic membrane. J Cell Biol 111: 731-41, 1990.
71. Polverini P, Cotran R Gimbrone MA Jr, Unanue ER: Activated macrophages induce vascular proliferation. Nature 1: 269-804-6,
72. Dugan JD Jr, Roberts AB, Sporn MB, Glaser BM: Transforming growth factor beta (TGF-beta) inhibits neovascularization in vivo. J Cell Biol 107: 579a, 1988.
73. Folkman J, Brem H: Angiogenesis and inflammation. In: Inflammation: Basic principles and clinical correlates (Gallin JI, Goldstein IM, Snydermann R, eds). New York, Raven Press Ltd. 1992, pp. 821-39.
74. Vargas J, Garcia E, Gutierrez F, Osorio C: Sintesis de acidos nucleicos y niveles de AMP ciclico en tumores murinos despues del tratamiento in vitro con anapsos. Arch Fac Med Madrid 40: 39-46, 1981.
75. Horvath A, Alvarado F, Szocs J, De Alvarado ZN, Padilla G: Metabolic effects of calagualine, an antitumoral saponine of Polypodium leucotomos. Nature 214: 1256-8, 1967.